---
title: "ARS Pharmaceuticals, Inc. (SPRY.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/SPRY.US.md"
symbol: "SPRY.US"
name: "ARS Pharmaceuticals, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T06:03:03.509Z"
locales:
  - [en](https://longbridge.com/en/quote/SPRY.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SPRY.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SPRY.US.md)
---

# ARS Pharmaceuticals, Inc. (SPRY.US)

## Company Overview

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [ars-pharma.com](https://ars-pharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:16.000Z

**Overall: D (0.70)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 230 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 1.92% |  |
| Net Profit YoY | -1165.02% |  |
| P/B Ratio | 11.61 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 712004388.54 |  |
| Revenue | 98986000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -136.40% | E |
| Profit Margin | -200.00% | E |
| Gross Margin | 53.17% | B |
| Revenue YoY | 1.92% | C |
| Net Profit YoY | -1165.02% | E |
| Total Assets YoY | -12.14% | E |
| Net Assets YoY | -73.22% | E |
| Cash Flow Margin | 88.43% | C |
| OCF YoY | 1.92% | C |
| Turnover | 0.32 | D |
| Gearing Ratio | 78.68% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - ARS Pharmaceuticals, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "1.92%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-1165.02%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "11.61",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "712004388.54",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "98986000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-136.40%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-200.00%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "53.17%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "1.92%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-1165.02%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-12.14%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-73.22%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "88.43%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "1.92%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.32",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "78.68%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -3.60 | 329/386 | - | - | - |
| PB | 11.61 | 397/386 | 7.50 | 6.82 | 5.64 |
| PS (TTM) | 7.19 | 143/386 | 14.65 | 9.24 | 7.09 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-17T04:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 5 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 7.17 |
| Highest Target | 32.00 |
| Lowest Target | 12.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/SPRY.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/SPRY.US/norm.md)
- [Related News](https://longbridge.com/en/quote/SPRY.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/SPRY.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**